Skip to main content

Advertisement

Table 3 Comparison of trials on LMWH versus VKA for treatment of VTE in cancer patients

From: Management of venous thromboembolism: an update

Trial Name CANTHANOX CLOT MAIN-LITE ONCENOX CATCH
Year of Publication [Ref] 2002 [43] 2003 [44] 2006 [45] 2006 [46] 2015 [47]
Design Open-label Open-label Open-label Open-label Open-label
Number of Patients 146 676 200 122 900
Treatment Protocol Enoxaparin 1.5 mg/kg daily Dalteparin 200 IU/kg once daily for the first month then 150 IU/kg for 5 months Tinzaparin 175 IU/kg once daily Enoxaparin 1 mg/kg every 12 h for 5 days then enoxaparin 1 mg/kg or 1.5 mg/kg daily Tinzaparin 175 IU/kg once daily
Duration of Therapy (months) 3 6 3 6 6
Primary Efficacy Outcome LMWH vs VKA (%) Combination of major bleeding or recurrent VTE: 10.5 vs 21.1 Recurrent symptomatic VTE: 9a vs 17 Recurrent symptomatic VTE: 7 vs 10 Recurrent symptomatic VTE: enoxaparin 1 mg vs. 1.5 mg vs VKA 6.8 vs 6.3 vs 10.0 Composite of recurrent symptomatic VTE, fatal PE, or incidental VTE: 7.2 vs 10.5
Safety Bleeding Outcomes LMWH vs VKA (%) Major bleeding: 7 vs 16; Fatal bleeding: 0 vs 8a Major bleeding: 6 vs 4; Any bleeding 14 vs 19 Major bleeding: 7 vs 7; Any bleeding: 27 vs 24 Major bleeding: enoxaparin 1 mg vs. 1.5 mg vs VKA : 6.5 vs 11.1 vs 2.9 Major bleeding: 2.7 vs 2.4 CRNM bleeding: 10.9a vs 15.3
  1. CRNM clinically relevant non-major, DOAC direct oral anticoagulants, LMWH low-molecular weight heparin, PE pulmonary embolism, VKA vitamin K antagonists, VTE venous thromboembolism
  2. aStatistically significant difference between the two groups